NLRP3 and COVID-19: In addition to its role in treating acute gout and pericarditis, evidence is emerging that colchicine might inhibit endovascular inflammation and provide clinical benefits in patients with coronary artery disease.14, 15, 16, 17 Given the activation of NLRP3 in COVID-19 and the presence of vascular endothelial inflammation, colchicine has been proposed as a treatment for SARS-CoV-2 associated inflammatory disease.